Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset alvelestat for AATD-LD on August 12, 2026 AATD-LD alpha-1 antitrypsin deficiency-associated lung disease Alvelestat Drugs, Orphan Fast Track Mereo BioPharma milestone payments Neutrophil Elastase Inhibitors royalties Sentynl upfront payments +
FDA Rejects CUTX-101 for Rare Copper Deficiency Due to Manufacturing Issues on October 01, 2025 biotech CUTX-101 Cyprium Therapeutics Fortress Hypocupremia manufacturing deficiencies Menkes disease rejection Sentynl United States Food and Drug Administration +